Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	RÁČIL Zdeněk RÁZGA Filip DRÁPALOVÁ Jana BUREŠOVÁ Lucie ŽÁČKOVÁ Daniela PALACKOVÁ Martina SEMERÁD Lukáš MALÁSKOVÁ Ludmila HALUZÍK Martin MAYER Jiří
Year of publication	2013
Type	Article in Periodical
Magazine / Source	Haematologica
MU Faculty or unit	Central European Institute of Technology
Citation
Web	http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1
Doi	http://dx.doi.org/10.3324/haematol.2013.086355
Field	Oncology and hematology
Keywords	Nilotinib; insulin resistance
Attached files	EL_1119840_Mechanism_of_impaired.pdf
Description	For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.
Related projects:	CEITEC - Central European Institute of Technology